XEN1120

About Xenon Pharmaceuticals

Xenon Pharmaceuticals is a Canadian biotech leader dedicated to developing life-changing medicines for neurological and psychiatric conditions. Its core strategy leverages a validated human genetics platform to de-risk ion channel drug discovery, resulting in a deep pipeline of 23 candidates, most notably the Phase 3 Kv7 opener azetukalner for epilepsy and depression. With a market cap of $5.23B and a seasoned leadership team, Xenon is transitioning from a discovery-focused entity to a late-stage clinical company with significant near-term catalysts.

Therapeutic Areas